The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...

Tumour Treating Fields (TTFields) present a completely different approach to cancer therapy, involving alternating electric ...

Multiple myeloma (MM) is an incurable haematological malignancy, but patient survival outcomes have been lately improved by recent advances in treatment. Despite this innovation, however, MM patients ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

The award from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

According to AZ, SERENA-6 is also the first pivotal trial to show the value of measuring circulating tumour DNA (ctDNA) to ...

Shareholders in the Nasdaq-listed German company, which is backed by billionaire investor and PayPal co-founder Peter Thiel, ...